Immunoassay formats applicable for clinical or point-of-care diagnostics fall into two broad classes. One which uses labeled secondary antibodies for signal transduction and the other which does not require the use of any labels. Comparison of the limits of detection (LoD) reported by these two sensing approaches over a wide range of detection techniques and target molecules in serum revealed that labeled techniques achieve 2-3 orders of magnitude better LoDs. Further, a vast majority of commercial tests and recent examples of technology translations are based on labeled assay formats. In light of this data, it is argued that extension of traditional labeled approaches and enhancing their functionality may have better clinical impact than the development of newer label-free techniques.
Box 1: Immunoassay format
The solid phase immunoassay format developed during the 60's and 70's is a method to detect the presence of proteins or other molecules a solid surface such as glass, nitrocellulose or (blue Y shaped objects in the figure) immobilized on the solid surface capture the target molecules (red spheres) from the sample containing other molecules (blue spheres) which may potentially interfere by binding to the antibodies. This is called non binding of the molecules (target or non appropriately chosen surface blocking steps s entirely due to the interaction of the sample with the immobilized antibodies. Recently researchers have also developed other ways to capture target mo (specific DNA sequences), instead of antibodies. In general, the basic idea of immunoassay is that receptor molecules immobilized on a solid surface capture specific targets from a sample. In any given assay there will be some accounted for while interpreting the measurement. depending on the detection of target receptor binding. conjugated with a label (blue Y shape with a green star attached to it) is used to bind to the target molecules captured by the immobilized antibodies making a sandwich structure. The signal is read out using properties of the label. For example, the label which emits light with a certain color colored product as in ELISA tests The labeling process and the incubation with secondary steps as well as increases the usage cost of such tests. As a result, several groups ha techniques not requiring the use of labe optical refractive index, electrical conductance or mass change associated with the capture of target molecules. Such assays are called label antibodies.
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Box 1: Immunoassay format
The solid phase immunoassay format developed during the 60's and 70's is a method to detect the presence of proteins or other molecules present in a sample using antibodies immobilized on uch as glass, nitrocellulose or Silicon [9] . As indicated in the figure, (blue Y shaped objects in the figure) immobilized on the solid surface capture the target d spheres) from the sample containing other molecules (blue spheres) which may potentially interfere by binding to the antibodies. This is called nonbinding of the molecules (target or non-specific molecules) to the solid surface is surface blocking steps so that the resultant signal from due to the interaction of the sample with the immobilized antibodies. Recently researchers have also developed other ways to capture target molecules, for example aptamers (specific DNA sequences), instead of antibodies. In general, the basic idea of immunoassay is that receptor molecules immobilized on a solid surface capture specific targets from a sample. In any given assay there will be some non-specific component of the signal which needs to be accounted for while interpreting the measurement. There are two broad classes of immunoassays depending on the detection of target receptor binding. One in which a secondary antibody label (blue Y shape with a green star attached to it) is used to bind to the target molecules captured by the immobilized antibodies making a sandwich structure. The out using properties of the label. For example, the label could be a with a certain color or an enzyme molecule which converts a substrate to a as in ELISA tests [10] . This type of detection is referred to ling process and the incubation with secondary antibodies introduce additional process steps as well as increases the usage cost of such tests. As a result, several groups ha techniques not requiring the use of labeled secondary antibodies. Instead, they may ndex, electrical conductance or mass change associated with the capture of target molecules. Such assays are called label-free assays as they do not use labeled secondary
Label-Free and Labeled Immunoassay Schemes
The solid phase immunoassay format developed during the 60's and 70's is a method to detect present in a sample using antibodies immobilized on indicated in the figure, antibodies (blue Y shaped objects in the figure) immobilized on the solid surface capture the target d spheres) from the sample containing other molecules (blue spheres) which may -specific binding. The specific molecules) to the solid surface is prevented by o that the resultant signal from the sensor is due to the interaction of the sample with the immobilized antibodies. Recently lecules, for example aptamers (specific DNA sequences), instead of antibodies. In general, the basic idea of immunoassay is that receptor molecules immobilized on a solid surface capture specific targets from a sample. In specific component of the signal which needs to be There are two broad classes of immunoassays One in which a secondary antibody label (blue Y shape with a green star attached to it) is used to bind to the target molecules captured by the immobilized antibodies making a sandwich structure. The could be a fluorophore or an enzyme molecule which converts a substrate to a This type of detection is referred to as labeled detection.
antibodies introduce additional process steps as well as increases the usage cost of such tests. As a result, several groups have developed tibodies. Instead, they may measure the ndex, electrical conductance or mass change associated with the capture of free assays as they do not use labeled secondary
Free and Labeled Immunoassay Schemes
Comparison of limit of detection of labeled and label-free sensors
Label-free sensors have witnessed decades of development with a veritable zoo of techniques available today exploiting physical effects as exotic as superconducting quantum interference [11] . However, in spite of this intense activity, most real-world tests including FDA approved tests are still based on labeled formats such as ELISA and immuno-fluorescence assays [12] and almost all recent examples from literature describing translation of diagnostic technology to real-world applications are also based on the labeled format [2, [5] [6] [7] [8] [13] [14] [15] [16] . It is therefore very important now to critically compare the performance of labeled and label-free technologies to understand if there are systematic reasons for the lack of prevalence for label-free technologies. To assess the current state of performance of label-free techniques, I compared the nearly 120 limit of detection (LoD) values reported for label-free and labeled methods for serum based biomarker detection. There were significant differences in the surface functionalization and assay protocols followed by different research groups reporting these LoDs. Consequently such a comparison may suffer from biases arising from the sensitivity of the LoD to the specific experimental protocols. To better compare these two approaches, I identified reports where labeled and label-free assays were performed simultaneously, eliminating any bias arising from differences in experimental protocols. Finally, I also examined recent examples describing translation of sensing techniques into real-world applications. It was found that labeled techniques significantly outperformed label-free techniques in all these contexts. In light of this observation, I argue that extension of traditional labeled assays into lab-on-chip formats and enhancing their performance using innovative signal read-out methods may have a better clinical impact than the frenzied development of newer label-free techniques we have witnessed in recent times.
The LoDs reported by various groups for a range of protein biomarkers, including those related to cancer were examined . Therefore, the data collected was a comprehensive representation of serum based labeled and label-free detection approaches. In order to extract the LoD 50 value in an objective manner, the data points were fitted with a smooth curve. As seen in Fig. 2 (a) , the LoD 50 value of labeled detection was about 0.1 pM (pico-Molar) while that of label-free detection was around 10 pM indicating a 3 orders of magnitude gap in LoDs in favor of labeled detection methods. An examination of the high performing label-free detection techniques, depicted as "label-free outliers" in Fig. 2 a) revealed that all of them used significant amplification of the signal by using secondary antibodies tagged with micron sized beads, nanoparticles or enzymes. Use of such tagged secondary antibodies is contrary to the label-free detection paradigm and it is debatable whether these techniques should indeed be classified as label-free. Such reports were classified in a new category called "Labelfree secondary amplified" and a reanalysis of the data was done. Out of the 53 data points in the label-free category, 30 of them, i.e. more than 50%, used secondary amplification. The CDF of the different sensing approaches classified into labeled, label-free and label-free secondary amplified is shown in Fig. 2 (b) . Understandably, amplification of the label-free signal using secondary antibodies results in an order of magnitude improvement achieving an LoD 50 value around 3 pM compared to the LoD 50 of about 30 pM for direct label-free detection. However this performance is still nearly two orders of magnitude worse than that achieved by labeled detection which has a LoD 50 around 0.1 pM.
To check if there was any correlation between reported LoDs with the molecular mass of the target biomarker, the data was re-plotted in the manner shown in Fig. 2 (c) . The horizontal axis is the reported LoD in pM (pico-molar) while the vertical axis is the molecular weight of the target biomarker. Red, green and blue stripes represent labeled, label-free secondary amplified and direct label-free LoDs respectively. We do not see any correlation associated with the different targets considered. In other words the conclusions drawn from Figs. 2 (a) and (b) are valid across the entire range of target biomarkers considered. The conclusion emerging from this analysis is that labeled detection techniques are 2-3 orders of magnitude more sensitive than label-free approaches and it is only after significant signal amplification using tagged secondary antibodies that label-free approaches can attain similar performance.
Box 2: Cumulative Distribution Function
Cumulative Distribution Function (CDF) is a function used in statistics to characterize the distribution of observed values of a variable [79] . CDF curves are generally normalized to a maximum of one so that the range of CDF is always from 0 to 1. The value of a normalized CDF curve for a variable V at x, denoted by CDF V (x), represents the probability that a random measurement of V would turn up a value less than x. For e.g. if the CDF for some variable V at x = 100 is 0.05, it means that it is very unlikely for measurements of V to yield values less than 100. We should expect the measurement of V to almost always yield values greater than 100. In the context of this article, CDF(x) represents the probability that a given research article in the respective detection category (labeled or label-free) would report a LoD less than x. For example, the value of CDF curve for label-free detection at LoD of 1 pM is about 0.25 ( Figure 2 (a)) while it is about 0.9 for labeled detection. This means that if we picked a random research article dealing with label-free detection there is only a 25% chance that it would report a LoD of less than 1 pM while there is a 90% chance that the reported LoD would be less than 1 pM if the article was dealing with labeled detection. This is the basis for the observation that labeled techniques appear to outperform label-free methods. To construct the approximate CDF curve from a set of observed values, we rank the observations in ascending order and use
where R(x) is the rank (position) of x in the sorted list of observations and N is the total number of observations in the set. We then plot CDF(x) against x for each observed value in the set to obtain the CDF curves shown in Fig. 2 shows that there is no correlation between the achieved LoDs and the molecular weight of the free secondary amplified shows the comparison of direct label-free and labeled LoDs measured simultaneously in the same assay eliminating variations arising from differences in experimental protocols. It is seen that every data point shows better performance of the labeled technique. The log10 ratio of the label-free to labeled LoD is plotted on the right vertical axis. The mean log10 LoD ratio is around 3 which supports the conclusion from Fig. 2 (a) and (b) that labeled techniques achieve 2-3 orders magnitude better LoDs compared to labelfree techniques.
Data from simultaneous labeled and label-free assays
As mentioned earlier, LoD is sensitive to surface functionalization methods and associated experimental protocols. As there are likely to be major variations in these parameters for the data shown in Fig. 2 (a) , the best way to compare the two different detection approaches would be to measure the same assay using a labeled and a label-free method simultaneously. Fig. 2 (d) , it is seen that labeled LoD was significantly better than the corresponding label-free LoD. Moreover, the mean log 10 ratio of label-free LoD to the labeled LoD of about 3 supports the conclusions drawn from the previous analysis, namely that labeled approaches achieve 2-3 orders of magnitude better LoDs than label-free techniques.
Examination of outlier technologies
It is interesting to examine the best performers in each category to identify techniques that show the highest promise. σ is the noise floor of measurement and S is the sensitivity of the measurement technique [80] . It is believed that the noise floor in the current generation of biosensors mostly arises from non-specific binding (NSB)
processes, for e.g., binding of interfering molecules to the receptors [81] . In this case, the noise floor will be the standard deviation of signal produced by a negative control sample, which in the case of serum based tests will be serum devoid of the target biomarker. In the case of labeled techniques, noise σ mainly arises from NSB of the secondary antibody to the target biomarker or unblocked sensor surface. However, in the case of label-free approaches, irrespective of whether they are amplified or not, noise σ can arise due to the NSB of the secondary antibody, NSB of the target biomarker, erosion of receptors [67] or similar phenomena related to the functionalization layers. In other words the noise floor of label-free detection is likely to be larger than that of labeled approaches. The improvement in LoD 50 for secondary antibody tagged amplified labelfree sensors arises from increased sensitivity (larger S) due to signal amplification. This is a plausible model to explain the observations in Fig. 2 .
Conclusions and implications for clinical assay development
Perhaps related to the observations made above, examination of commercial tests for FDA approved serum biomarkers [12] Fluorophore: A fluorophore is a molecule which can absorb light around a peak absorption wavelength and emit light at slightly longer wavelengths. They can be used for labelling secondary antibodies in labelled immunoassays.
Immunoassay:
Immunoassay is the term used to describe the method to test for the presence of a molecule of interest, referred to as the target, using another molecule having a specific affinity for the target, such as an antibody against the target. Fluorescence/ELISA (ts = sens* OR ts = assay) AND (ti = fluor* OR ti = ELISA) AND (ts = analyte) Label-free (LF) generic All (ts = sens* OR ts = assay) AND (ts = "label free" OR ts = label-free) AND (ts = analyte)
Limit of detection All (ts = "limit of detection") AND (ts = analyte) LF Optical SPR (ts = sens* OR ts = assay) AND (ts = SPR OR ts = plasmon*) AND (ts = analyte) Optical cavities, Micro-ring resonators (ts = sens* OR ts = assay) AND (ts = silicon OR ts = resona*) AND (ts = analyte)
Interferometry
(ts = sens* OR ts = assay) AND (ts = interfer*) AND (ts = analyte) General Optical (ts = sens* OR ts = assay) AND (ts = optic*) AND (ts = analyte) Reflectance (ts = sens* OR ts = assay) AND (ts = reflect*) AND (ts = analyte) LF Electrical Nanowire (ts = sens* OR ts = assay) AND (ts = silicon OR ts = nanowire OR ts = nano-wire OR ts = CNT OR ts = nano-tube) AND (ts = analyte) Impedance (ts = sens* OR ts = assay) AND (ts = imped*) AND (ts = analyte) LF Mass/mech cantilever (ts = sens* OR ts = assay) AND (ts = cantilever OR ts = MEMS OR ts = silicon OR ts = micro-mech* OR ts = micromech* OR ts = resona*) AND (ts = analyte) QCM (ts = sens* OR ts = assay) AND (ts = QCM OR ts = "quartz crystal") AND (ts = analyte) LF Electrochem Electrochemical (ts = sens* OR ts = assay) AND (ts = electroche*) AND (ts = analyte) LF magnetic (ts = sens* OR ts = assay) AND (ts = *magnet*) AND (ts = analyte)
The term "analyte" in the search strings above was substituted with the appropriate biomarker, e.g. PSA, IL6 and so on for each category listed above
